Abstract: In some implementations, an enrichment engine may receive a first entry. The enrichment engine may generate a normalized first entry by using subword tokenization of the first entry. The enrichment engine may execute a plurality of searches concurrently, including: a first search configured to map a portion of the normalized first entry to a first result using regular expressions and fuzzy matching, a second search configured to provide the normalized first entry to a machine learning model in order to receive a second result, and a third search configured to map a vectorized version of the normalized first entry to a third result in a vector database. The enrichment engine may determine a selected result from the first result based on the first search, the second result based on the second search, or the third result based on the third search. The enrichment engine may return the selected result.

Abstract: An engineering design tool and methods for using the same are disclosed. A method may include receiving at least one parent design and generating a plurality of first-generation design copies that each include a characteristic that has mutated from the parent design. New generations of design copies are successively produced from the additional design copies based on fitness testing the new generations of design copies. Characteristics from intergenerational design copies that are not within the same generation are utilized to perform intergenerational crossover, and a likelihood of a mutation of a design copy is increased in response to a threshold number of generations without an improvement in a fitness score of a design copy. New generations continue to be successively produced until a likelihood that any design copy with a higher fitness score will be produced is below a statistical threshold.

Abstract: An engineering design tool and methods for using the same are disclosed. A method may include receiving at least one parent design and generating a plurality of first-generation design copies that each include a characteristic that has mutated from the parent design. New generations of design copies are successively produced from the additional design copies based on fitness testing the new generations of design copies. Characteristics from intergenerational design copies that are not within the same generation are utilized to perform intergenerational crossover, and a likelihood of a mutation of a design copy is increased in response to a threshold number of generations without an improvement in a fitness score of a design copy. New generations continue to be successively produced until a likelihood that any design copy with a higher fitness score will be produced is below a statistical threshold.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The invention pertains to prodrugs of 9-aminomethyl substituted tetracycline compounds, methods of using the compounds, and pharmaceutical compositions containing them.

Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: Aminomethyl substituted tetracycline compounds, pharmaceutical compositions, and methods of use thereof are discussed.

Abstract: Aminomethyl substituted tetracycline compounds, pharmaceutical compositions, and methods of use thereof are discussed.

Abstract: 10-Substituted tetracycline compounds are described.

Abstract: The invention pertains to prodrugs of 9-aminomethyl substituted tetracycline compounds, methods of using the compounds, and pharmaceutical compositions containing them.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.